|
Medication
|
Number of patients who used (%)
|
No response (%)
|
Partial response (%)
|
Remission (%)
|
|---|
|
NSAID
|
44 (100)
|
27/44 (61.4)
|
11/44 (25)
|
6/44 (13.6)
|
|
Methotrexatea
|
24 (54.5)
|
11/24 (45.8)
|
6/24 (25)
|
7/24 (29.1)
|
|
Pamidronate
|
6 (13.6)
|
3/6 (50)
|
1/6b (16.7)
|
0
|
|
Adalimumab
|
15 (34)
|
5/15c (33.3)
|
6/15 (40)
|
4/15 (16.7)
|
|
Infliximab
|
7 (15.9)
|
2/7 (28.6)
|
3/7 (42.8)
|
2/7 (28.6)
|
|
Etanercept
|
4 (9.1)
|
2/4 (50)
|
1/4 (25)
|
1/4 (25)
|
- a. Monotherapy; does not include those who received methotrexate as an adjunct to TNF blocker
- b. 2 patients have received < 3 months treatment
- c. 1 discontinued early due to adverse reaction
